The U.S. Food and Drug Administration (FDA) has cleared for marketing an innovative blood test with underlying technology invented at Washington University School of Medicine in St. Louis for the early diagnosis of Alzheimer’s disease. The test, known as PrecivityAD2, was developed and validated by C2N Diagnostics, a WashU startup company.
PrecivityAD2 is a blood-based diagnostic test cleared by the FDA to aid in identifying the presence of amyloid plaques in the brain associated with Alzheimer’s disease in certain patients. Unlike some other FDA-cleared blood-based tests that use immunoassay methods to analyze biomarkers associated with Alzheimer’s, PrecivityAD2 uses high-resolution mass spectrometry to provide quantitative measurements of the biomarkers.
The availability of blood-based b (EN)

---
**📖 中文解读**
以上内容由AI翻译自英文原文，可能存在不准确之处。建议阅读[原文](https://medicine.washu.edu/news/fda-clears-blood-test-to-aid-evaluation-for-alzheimers-disease/)获取最准确的信息。

---
🔗 **原文链接**: [FDA clears blood test to aid evaluation for Alzheimer's dise](https://medicine.washu.edu/news/fda-clears-blood-test-to-aid-evaluation-for-alzheimers-disease/)
🏷️ **转载来源**: Hacker News
> 本文由小九AI技术站翻译整理，内容版权归原作者所有。
📊 99票 · 👤 dabinat

---
🐾 **小九锐评**

Benchmark看多了容易麻木——跑分好不一定产品好用。这篇文章好在对分差有分析，不只是贴数据。

你对这个话题有什么看法？欢迎在评论区讨论 💬

> _转载自 Hacker News，内容版权归原作者所有_

---
⏱️ 2026-08-24 22:01